Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Human Immunodeficiency Virus | Methodology

In-house ELISA protocols for capsid p24 detection of diverse HIV isolates

Authors: Mariano A. Molina, Monique Vink, Ben Berkhout, Elena Herrera-Carrillo

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Background

The capsid p24 (CA-p24) antigen is a component of the viral capsid of human immunodeficiency virus (HIV) that has been commonly used for clinical diagnosis and monitoring of HIV infections in Enzyme-linked Immunosorbent Assays (ELISAs). Commercial CA-p24 ELISAs are widely used in research settings, but these kits are costly and have limited breadth for detecting diverse HIV isolates.

Methods

Commercial CA-p24 antibodies were used as capture and detection antibodies. Specific CA-p24 ELISAs were established with these antibodies and tested for the detection of HIV-1 isolates with the aim of developing in-house protocols to recognize HIV-1 infections in vitro for research purposes.

Results

Here we present four protocols for in-house ELISAs to detect HIV CA-p24 using commercial antibodies. The assays were able to detect the CA-p24 antigen of different HIV-1 isolates tested. Comparison between the protocols showed that these in-house ELISAs exhibit high specificity, sensitivity, and reproducibility for CA-p24 quantitation but their reactivity varied per HIV-1 isolate and subtype.

Conclusions

These optimized ELISA protocols represent valuable tools to investigate HIV-1 infections in research facilities at a lower price than commercial CA-p24 kits.
Appendix
Available only for authorised users
Literature
2.
go back to reference Menéndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43(1):16–29.CrossRefPubMed Menéndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43(1):16–29.CrossRefPubMed
3.
go back to reference Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, et al. The case for an HIV cure and how to get there. Lancet HIV. 2021;8(1):e51–8.CrossRefPubMed Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, et al. The case for an HIV cure and how to get there. Lancet HIV. 2021;8(1):e51–8.CrossRefPubMed
4.
go back to reference Ng’uni T, Chasara C, Ndhlovu ZM. Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Front Immunol. 2020;11. Ng’uni T, Chasara C, Ndhlovu ZM. Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Front Immunol. 2020;11.
5.
go back to reference Herrera-Carrillo E, Gao Z, Berkhout B. CRISPR therapy towards an HIV cure. Brief Funct Genomics. 2020;19(3):201–8.CrossRefPubMed Herrera-Carrillo E, Gao Z, Berkhout B. CRISPR therapy towards an HIV cure. Brief Funct Genomics. 2020;19(3):201–8.CrossRefPubMed
6.
go back to reference Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244–8.CrossRefPubMedPubMedCentral Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244–8.CrossRefPubMedPubMedCentral
7.
go back to reference Mu Z, Haynes BF, Cain DW. HIV mRNA vaccines—progress and future paths. Vaccines. 2021;9(2). Mu Z, Haynes BF, Cain DW. HIV mRNA vaccines—progress and future paths. Vaccines. 2021;9(2).
8.
go back to reference Fitzgerald N, Cross M, Shea S, Fox J. Diagnosing acute HIV infection at point of care: a retrospective analysis of the sensitivity and specificity of a fourth-generation point-of-care test for detection of HIV core protein p24. Sex Transm Infect. 2017;93(2):100.CrossRefPubMed Fitzgerald N, Cross M, Shea S, Fox J. Diagnosing acute HIV infection at point of care: a retrospective analysis of the sensitivity and specificity of a fourth-generation point-of-care test for detection of HIV core protein p24. Sex Transm Infect. 2017;93(2):100.CrossRefPubMed
9.
go back to reference Levinger C, Howard JN, Cheng J, Tang P, Joshi A, Catalfamo M, et al. An ultrasensitive planar array p24 Gag ELISA to detect HIV-1 in diverse biological matrixes. Sci Rep. 2021;11(1):23682.CrossRefPubMedPubMedCentral Levinger C, Howard JN, Cheng J, Tang P, Joshi A, Catalfamo M, et al. An ultrasensitive planar array p24 Gag ELISA to detect HIV-1 in diverse biological matrixes. Sci Rep. 2021;11(1):23682.CrossRefPubMedPubMedCentral
10.
go back to reference Sena-Esteves M, Gao G. Monitoring lentivirus vector stocks for replication-competent viruses. Cold Spring Harbor Protocols. 2018;2018(4):pdb.prot095703. Sena-Esteves M, Gao G. Monitoring lentivirus vector stocks for replication-competent viruses. Cold Spring Harbor Protocols. 2018;2018(4):pdb.prot095703.
11.
12.
go back to reference Cragin L, Pan F, Peng S, Zenilman JM, Green J, Doucet C, et al. Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States. HIV Clin Trials. 2012;13(1):11–22.CrossRefPubMed Cragin L, Pan F, Peng S, Zenilman JM, Green J, Doucet C, et al. Cost-effectiveness of a fourth-generation combination immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen for the detection of HIV infections in the United States. HIV Clin Trials. 2012;13(1):11–22.CrossRefPubMed
13.
go back to reference Fan P, Li X, Su W, Kong W, Kong X, Wang Z, et al. Enhanced sensitivity for detection of HIV-1 p24 antigen by a novel nuclease-linked fluorescence oligonucleotide assay. PLoS ONE. 2015;10(4): e0125701.CrossRefPubMedPubMedCentral Fan P, Li X, Su W, Kong W, Kong X, Wang Z, et al. Enhanced sensitivity for detection of HIV-1 p24 antigen by a novel nuclease-linked fluorescence oligonucleotide assay. PLoS ONE. 2015;10(4): e0125701.CrossRefPubMedPubMedCentral
14.
go back to reference Frezza C, Grelli S, Federico M, Marino-Merlo F, Mastino A, Macchi B. Testing anti-HIV activity of antiretroviral agents in vitro using flow cytometry analysis of CEM-GFP cells infected with transfection-derived HIV-1 NL4-3. J Med Virol. 2016;88(6):979–86.CrossRefPubMed Frezza C, Grelli S, Federico M, Marino-Merlo F, Mastino A, Macchi B. Testing anti-HIV activity of antiretroviral agents in vitro using flow cytometry analysis of CEM-GFP cells infected with transfection-derived HIV-1 NL4-3. J Med Virol. 2016;88(6):979–86.CrossRefPubMed
15.
go back to reference Vetter BN, Orlowski V, Niederhauser C, Walter L, Schüpbach J. Impact of naturally occurring amino acid variations on the detection of HIV-1 p24 in diagnostic antigen tests. BMC Infect Dis. 2015;15(1):468.CrossRefPubMedPubMedCentral Vetter BN, Orlowski V, Niederhauser C, Walter L, Schüpbach J. Impact of naturally occurring amino acid variations on the detection of HIV-1 p24 in diagnostic antigen tests. BMC Infect Dis. 2015;15(1):468.CrossRefPubMedPubMedCentral
16.
go back to reference Vetter BN, Orlowski V, Fransen K, Niederhauser C, Aubert V, Brandenberger M, et al. Generation of a recombinant gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests. PLoS ONE. 2014;9(10): e111552.CrossRefPubMedPubMedCentral Vetter BN, Orlowski V, Fransen K, Niederhauser C, Aubert V, Brandenberger M, et al. Generation of a recombinant gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests. PLoS ONE. 2014;9(10): e111552.CrossRefPubMedPubMedCentral
17.
go back to reference Ly TD, Plantier JC, Leballais L, Gonzalo S, Lemée V, Laperche S. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24Ag according to genotype could compromise the diagnosis of early HIV infection. J Clin Virol. 2012;55(2):121–7.CrossRefPubMed Ly TD, Plantier JC, Leballais L, Gonzalo S, Lemée V, Laperche S. The variable sensitivity of HIV Ag/Ab combination assays in the detection of p24Ag according to genotype could compromise the diagnosis of early HIV infection. J Clin Virol. 2012;55(2):121–7.CrossRefPubMed
18.
go back to reference Merbah M, Onkar S, Grivel J-C, Vanpouille C, Biancotto A, Bonar L, et al. Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes. J Virol Methods. 2016;230:45–52.CrossRefPubMedPubMedCentral Merbah M, Onkar S, Grivel J-C, Vanpouille C, Biancotto A, Bonar L, et al. Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes. J Virol Methods. 2016;230:45–52.CrossRefPubMedPubMedCentral
19.
go back to reference Gao Z, Fan M, Das AT, Herrera-Carrillo E, Berkhout B. Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA. Nucleic Acids Res. 2020;48(10):5527–39.CrossRefPubMedPubMedCentral Gao Z, Fan M, Das AT, Herrera-Carrillo E, Berkhout B. Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA. Nucleic Acids Res. 2020;48(10):5527–39.CrossRefPubMedPubMedCentral
20.
go back to reference Liu Y, Jeeninga RE, Klaver B, Berkhout B, Das AT. Transient CRISPR-cas treatment can prevent reactivation of HIV-1 replication in a latently infected T-cell line. Viruses. 2021;13(12). Liu Y, Jeeninga RE, Klaver B, Berkhout B, Das AT. Transient CRISPR-cas treatment can prevent reactivation of HIV-1 replication in a latently infected T-cell line. Viruses. 2021;13(12).
21.
go back to reference Fan M, Berkhout B, Herrera-Carrillo E. A combinatorial CRISPR-Cas12a attack on HIV DNA. Mol Therapy Methods Clin Dev. 2022;25:43–51.CrossRef Fan M, Berkhout B, Herrera-Carrillo E. A combinatorial CRISPR-Cas12a attack on HIV DNA. Mol Therapy Methods Clin Dev. 2022;25:43–51.CrossRef
22.
go back to reference Jeeninga RE, Jan B, van den Berg H, Berkhout B. Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology. 2006;3(1):64.CrossRefPubMedPubMedCentral Jeeninga RE, Jan B, van den Berg H, Berkhout B. Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology. 2006;3(1):64.CrossRefPubMedPubMedCentral
23.
go back to reference Zou W, Xing J, Zou S, Jiang M, Chen X, Chen Q, et al. HIV-1LAI Nef blocks the development of hematopoietic stem/progenitor cells into myeloid-erythroid lineage cells. Biol Direct. 2021;16(1):27.CrossRefPubMedPubMedCentral Zou W, Xing J, Zou S, Jiang M, Chen X, Chen Q, et al. HIV-1LAI Nef blocks the development of hematopoietic stem/progenitor cells into myeloid-erythroid lineage cells. Biol Direct. 2021;16(1):27.CrossRefPubMedPubMedCentral
24.
go back to reference Peden K, Emerman M, Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology. 1991;185(2):661–72.CrossRefPubMed Peden K, Emerman M, Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology. 1991;185(2):661–72.CrossRefPubMed
25.
go back to reference Datta R, Roy Chowdhury R, Manjunath K, Hanna Luke E, Varadarajan R. A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing. Proc Natl Acad Sci. 2020;117(47):29584–94.CrossRefPubMedPubMedCentral Datta R, Roy Chowdhury R, Manjunath K, Hanna Luke E, Varadarajan R. A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing. Proc Natl Acad Sci. 2020;117(47):29584–94.CrossRefPubMedPubMedCentral
26.
27.
go back to reference Li G, Verheyen J, Rhee S-Y, Voet A, Vandamme A-M, Theys K. Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology. 2013;10(1):126.CrossRefPubMedPubMedCentral Li G, Verheyen J, Rhee S-Y, Voet A, Vandamme A-M, Theys K. Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology. 2013;10(1):126.CrossRefPubMedPubMedCentral
28.
go back to reference Fischer Douglas K, Saito A, Kline C, Cohen R, Watkins Simon C, Yamashita M, et al. CA mutation N57A has distinct strain-specific HIV-1 capsid uncoating and infectivity phenotypes. J Virol. 2019;93(9):e00214-e219.PubMedPubMedCentral Fischer Douglas K, Saito A, Kline C, Cohen R, Watkins Simon C, Yamashita M, et al. CA mutation N57A has distinct strain-specific HIV-1 capsid uncoating and infectivity phenotypes. J Virol. 2019;93(9):e00214-e219.PubMedPubMedCentral
30.
go back to reference Miedouge M, Grèze M, Bailly A, Izopet J. Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard. J Clin Virol. 2011;50(1):57–60.CrossRefPubMed Miedouge M, Grèze M, Bailly A, Izopet J. Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard. J Clin Virol. 2011;50(1):57–60.CrossRefPubMed
31.
go back to reference Kaur P, Khong WX, Wee SY, Tan EL, Pipper J, Koay E, et al. Clinical evaluation of a low cost, in-house developed real-time RT-PCR human immunodeficiency virus type 1 (HIV-1) quantitation assay for HIV-1 infected patients. PLoS ONE. 2014;9(3): e89826.CrossRefPubMedPubMedCentral Kaur P, Khong WX, Wee SY, Tan EL, Pipper J, Koay E, et al. Clinical evaluation of a low cost, in-house developed real-time RT-PCR human immunodeficiency virus type 1 (HIV-1) quantitation assay for HIV-1 infected patients. PLoS ONE. 2014;9(3): e89826.CrossRefPubMedPubMedCentral
32.
go back to reference Curtis KA, Rudolph DL, Pan Y, Delaney K, Anastos K, DeHovitz J, et al. Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection. PLoS ONE. 2021;16(7): e0242641.CrossRefPubMedPubMedCentral Curtis KA, Rudolph DL, Pan Y, Delaney K, Anastos K, DeHovitz J, et al. Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection. PLoS ONE. 2021;16(7): e0242641.CrossRefPubMedPubMedCentral
33.
go back to reference Barletta JM, Edelman DC, Constantine NT. Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen. Am J Clin Pathol. 2004;122(1):20–7.CrossRefPubMed Barletta JM, Edelman DC, Constantine NT. Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen. Am J Clin Pathol. 2004;122(1):20–7.CrossRefPubMed
34.
go back to reference Herrera-Carrillo E, Paxton WA, Berkhout B. The search for a T cell line for testing novel antiviral strategies against HIV-1 isolates of diverse receptor tropism and subtype origin. J Virol Methods. 2014;203:88–96.CrossRefPubMed Herrera-Carrillo E, Paxton WA, Berkhout B. The search for a T cell line for testing novel antiviral strategies against HIV-1 isolates of diverse receptor tropism and subtype origin. J Virol Methods. 2014;203:88–96.CrossRefPubMed
35.
go back to reference van’t WoutAngélique B, Blaak H, Ran Leonie J, Brouwer M, Kuiken C, Schuitemaker H. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J Virol. 1998;72(6):5099–107.CrossRef van’t WoutAngélique B, Blaak H, Ran Leonie J, Brouwer M, Kuiken C, Schuitemaker H. Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J Virol. 1998;72(6):5099–107.CrossRef
36.
go back to reference Pollakis G, Abebe A, Kliphuis A, ChalabyMoustapha IM, Bakker M, Mengistu Y, et al. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol. 2004;78(6):2841–52.CrossRefPubMedPubMedCentral Pollakis G, Abebe A, Kliphuis A, ChalabyMoustapha IM, Bakker M, Mengistu Y, et al. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol. 2004;78(6):2841–52.CrossRefPubMedPubMedCentral
Metadata
Title
In-house ELISA protocols for capsid p24 detection of diverse HIV isolates
Authors
Mariano A. Molina
Monique Vink
Ben Berkhout
Elena Herrera-Carrillo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02242-5

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.